# A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)

> **NCT02015312** · PHASE2 · COMPLETED · sponsor: **Florian Michel** · enrollment: 38 (actual)

## Conditions studied

- Light Chain (AL) Amyloidosis
- Cardiac Involvement

## Interventions

- **DRUG:** Epigallocatechin-3-gallate (EGCG)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02015312
- **Lead sponsor:** Florian Michel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2017-10-11
- **Final completion:** 2017-10-11
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015312, "A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02015312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*